Changes included the following: -Revised to indicate a minimum three-hour observation period after the first and second subcutaneous injections (from no such limit for study center observation after SC administration). - Revised Inclusion Criteria to specify that in addition to prohibition on sperm donation for the specified duration, ova donation for assisted reproduction is also prohibited. The duration for males was revised to 220 days (from 6 months).

Changes included the following: - Overall Design revised to remove a minimum of 7 days screening period requirement and updated 'up to 28 days', and updated the number of Investigators and number of study centers from 3 to 5. - Updated Background to reflect Phase I Study results (ANB019-001). - Inclusion Criteria: Added SI and conventional units for hemoglobin, white blood cell count, platelets, and serum creatinine. - Exclusion Criteria: Text revised to clarify the requirement to stop all systemic conventional therapies (eg. cyclosporine, methotrexate, and retinoid) the day the study drug is administered and remove definition of regular alcohol consumption and excessive smoking. - Removed Meals and Dietary Restrictions. - included guidance for using rescue medication in the form of topical corticosteroids (eg. betamethasone valerate ointment and cream, mometasone furoate ointment and cream) and guidance for adding any systemic psoriasis medication that is likely to impact psoriasis signs and symptoms (eg. cyclosporine, methotrexate, retinoid). - Removed the section 8.1.4 describing assessment of body surface area affected by GPP. - Updated timing of bidirectional posterior-anterior and lateral view chest X-ray. - Added text regarding follow-up visits in case of early discontinuation. - Added text to indicate that a minimum 3 hour observation period is required after the first and second SC injections. - Storage duration of biomarker samples and immunogenicity samples was updated to 5 years from 1 year. - Added text to indicate that “only samples within the stability window of the assay will be analyzed”.

Changes included the following: - Updated the number of Investigators and number of study centers from 5 to 8-10. - Added an additional secondary endpoint to assess the proportion of subjects achieving a score of 0 or 1 on the Generalized Pustular Psoriasis Physician’s Global Assessment scale. Additional wording added to the secondary endpoints for PK analysis; moved immunogenicity objective (to assess ADA) from exploratory to secondary endpoint; retitled tertiary/exploratory endpoints section to exploratory endpoints. - Revised the screening period from "up to 28 days" to "up to 42 days (Week -0)." - Added Table to detail the sample collection and time points for PK and ADA testing. - Inclusion Criteria revised to to increase the upper age limit from 65 to 75, define the limit of ALT and AST to ≤ 2 × ULN, and revise disease criteria for study entry. - Exclusion criteria revised to remove 2 examples of other forms of psoriasis that were excluded from participation. - Added wording to clarify that study treatment may be interrupted only once before being permanently discontinued. - New section added to describe the GPPPGA scale. - Clarified that ECGs will be reviewed by the central laboratory "for quality and interpretation" and that ECG data would not be entered into EDC with the exception of clinical significance. Photography language was revised to describe a standardized approach for collection of photographs and the process for transfer and quality review. - Added a clarification that Investigator may review laboratory assessments to make a decision about safety or to determine subject eligibility for the study. - Genetics language revised to characterize additional DNA/RNA testing and optional pharmacogenomic testing. - Text added to better characterize the presentation of statistical data for ADA status and efficacy and safety endpoints - Added 3 references - Added new appendix to support added secondary endpoint of the GPPPGA assessment.

Changes included the following: - Revised the secondary objectives to remove change from Baseline in GPPPGA score at all study visits and to assess change in Dermatology Life Quality Index (DLQI) total score instead of improvement in DLQI total score at all visits. Exploratory endpoint was revised for skin biopsies to assess IL-8 dendritic cells, not IL-6 dendritic cells. Removed references to logistic regression model using logit link. - Added one paragraph in Benefit/Risk Assessment about an SAE of sepsis that has been reported during the study for 1 subject. - Inclusion Criteria that specified the enrollment of subjects with or without a history of PP and PsA was removed. A statement was added that any laboratory values that are out-of-range at Screening will be left to the Investigator’s discretion as to whether or not a subject is eligible. - Exclusion Criteria modified to include squamous cell carcinoma deemed fully treatable by the Investigator as permissible. - Clarified the language around dose administration and to state that infusions may be slowed for subjects experiencing infusion-related reactions. - Revised the statement on collection of AEs to include any occurring through End of Study. - Clarified PK sample collection and documentation. - Removed the ITT Analysis Set and replaced with Full Analysis Set (FAS). Removed any references to randomization. The PPS will now be based on the FAS instead of the ITT set. Additional text was added to clarify use of the PK analysis set. - Added a clarification on the analysis of clinical response and Clinical Global Impression (CGI) score. - Clarified that secondary endpoints will be analyzed at all study visits through Week 16 for modified JDA SI score, descriptive statistics, GPPPGA score, and PASI. - Included a statement that summary statistics will be provided for average DLQI scores instead of absolute scores, in addition to the percent change from Baseline through Week 16.

Changes included the following: - The sentence permitting the Investigator to assess eligibility in consultation with the Medical Monitor and the Sponsor, for those subject who fail to meet laboratory screening criteria, has been removed.